Department of Neurology, North Zealand Hospital, University of Copenhagen, Dyrehavevej 29, 3400, Hilleroed, Denmark.
J Neurooncol. 2017 Nov;135(2):335-342. doi: 10.1007/s11060-017-2579-5. Epub 2017 Jul 27.
Primary brain tumors frequently cause considerable functional impairments and the survival time when diagnosed with glioblastoma is 14.6 months. The aim of this study was to examine if baseline postural control and walking ability in patients with glioblastoma could predict long term walking ability and 1 year mortality. Data were gathered from prospective recordings in a brain cancer database supplemented by retrospective review of electronic patient records. We included 109 patients with glioblastoma, 47 women and 62 men with mean age 65 years. At admission 84 patients were tested with Berg Balance Scale and 57 were tested with 10 meter walk test. Binary logistic regression analysis showed no statistical significance in favour of the 10 meter walk test. Berg Balance Scale showed an ability to predict walking ability 4-8 months after admission. The risk of dying within a year was 6.9 times higher in patients who lost their ability to walk within 4-8 months of the first admission. This study showed that Berg Balance Scale has some ability to predict the loss of walking ability 4-8 months after admission. This could be an important indicator pin pointing patients most in need of more intensive specialized neurorehabilitation efforts early in the disease course.
原发性脑肿瘤常导致严重的功能障碍，胶质母细胞瘤患者的诊断存活时间为 14.6 个月。本研究旨在探讨胶质母细胞瘤患者的基线姿势控制和步行能力是否可以预测长期步行能力和 1 年死亡率。数据来自脑癌数据库的前瞻性记录，并通过电子病历的回顾性审查进行补充。我们纳入了 109 名胶质母细胞瘤患者，其中 47 名女性，62 名男性，平均年龄 65 岁。入院时，84 名患者接受 Berg 平衡量表测试，57 名患者接受 10 米步行测试。二项逻辑回归分析显示，10 米步行测试无统计学意义。Berg 平衡量表显示出在入院后 4-8 个月预测步行能力的能力。在首次入院后 4-8 个月内丧失行走能力的患者，其一年内死亡的风险是能够行走的患者的 6.9 倍。本研究表明，Berg 平衡量表在入院后 4-8 个月内具有一定的预测丧失行走能力的能力。这可能是一个重要的指标，可以在疾病早期确定最需要更强化的专门神经康复治疗的患者。
